Introduction: Glioblastoma multiforme (GBM) is the most prevalent primary neoplasm of the
brain. Moreover, the prognosis of patients with GBM has been poor, with almost uniform …

Question: What is the safety and efficacy of interstitial chemotherapy with carmustine-loaded
polymers (Gliadel wafers: MGI Pharma, Bloomington, MN, USA) in the treatment of newly …

Malignant gliomas represent the majority of primary brain tumors, and the prognosis of the
patients afflicted with these tumors has been historically dismal, with almost uniform …

Abstract Background Carmustine-releasing wafers (Gliadel®) have been available and
reimbursed in France since 2005. Methods A retrospective multicenter study was conducted …

The advent of interstitial chemotherapy has significantly increased therapeutic options for
patients with malignant glioma. Interstitial chemotherapy can deliver high concentrations of …

Glioblastoma multiforme (GBM) is the most aggressive brain tumor. Standard treatment
includes surgery, radiation and chemotherapy. Prognosis is dismal with an average survival …

High-grade glioma is a devastating disease that leaves the majority of its victims dead within
2 years. To meaningfully increase survival, a trimodality approach of surgery, radiation, and …

Malignant gliomas are very difficult neoplasms for clinicians to treat. The reason for this is
multifaceted. Many treatments that are effective for systemic cancer are unable to cross the …

Glioblastoma multiforme (GBM) is the most common form of primary brain cancer and has
the highest morbidity rate and current treatments result in a bleak 5-year survival rate of …

Abstract Carmustine wafers (CW; Gliadel® wafers) are approved to treat newly-diagnosed
high-grade glioma (HGG) and recurrent glioblastoma. Widespread use has been limited for …